Pfizer Inc. (NYSE:PFE) Shares Sold by Paradigm Asset Management Co. LLC

Paradigm Asset Management Co. LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,033 shares of the biopharmaceutical company’s stock after selling 1,200 shares during the quarter. Paradigm Asset Management Co. LLC’s holdings in Pfizer were worth $1,325,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Clifford Swan Investment Counsel LLC lifted its position in Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after acquiring an additional 18,611 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $255,000. KLCM Advisors Inc. lifted its holdings in shares of Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares during the period. Finally, Farmers Trust Co. lifted its holdings in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after buying an additional 4,410 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PFE. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley raised their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $35.86.

Check Out Our Latest Stock Analysis on Pfizer

Pfizer Price Performance

Pfizer stock traded up $0.19 during mid-day trading on Monday, hitting $28.88. 22,589,100 shares of the company were exchanged, compared to its average volume of 42,365,793. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The business’s 50 day simple moving average is $27.27 and its two-hundred day simple moving average is $27.92. The company has a market capitalization of $163.65 billion, a P/E ratio of -481.25, a PEG ratio of 1.13 and a beta of 0.63. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 earnings per share. Analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.82%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.